A novel cereblon modulator recruits GSPT1 to the CRL4 CRBN ubiquitin ligase

Nature

Volumn 535, Issue 7611, 2016, Pages 252-257

  Matyskiela, Mary E ^a   Lu, Gang ^a   Ito, Takumi ^b   Pagarigan, Barbra ^a   Lu, Chin Chun ^a   Miller, Karen ^a   Fang, Wei ^a   Wang, Nai Yu ^a   Nguyen, Derek ^a   Houston, Jack ^a   Carmel, Gilles ^a   Tran, Tam ^a   Riley, Mariko ^a   Nosaka, Lyn'Al ^c   Lander, Gabriel C ^c   Gaidarova, Svetlana ^a   Xu, Shuichan ^a   Ruchelman, Alexander L ^a   Handa, Hiroshi ^b   Carmichael, James ^a   Daniel, Thomas O ^a   Cathers, Brian E ^a   Lopez Girona, Antonia ^a   Chamberlain, Philip P ^a   more..

^a CELGENE CORPORATION   (United States)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CC 885; CEREBLON; CRL4 CRBN UBIQUITIN LIGASE; GLUTATHIONE TRANSFERASE T1; GLYCINE; IMMUNOMODULATING AGENT; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; CARBANILAMIDE DERIVATIVE; CC-885; CRBN PROTEIN, HUMAN; DDB1 PROTEIN, HUMAN; DNA BINDING PROTEIN; IKAROS TRANSCRIPTION FACTOR; MULTIPROTEIN COMPLEX; PEPTIDE HYDROLASE; PEPTIDE-CHAIN-RELEASE FACTOR 3; PROTEIN BINDING; THALIDOMIDE; TRANSLATION TERMINATION FACTOR;

BRAIN; CANCER; CELLS AND CELL COMPONENTS; DRUG; ENZYME ACTIVITY; HOMOLOGY; MUTATION; PROTEIN; TUMOR;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CHEMOSENSITIVITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG POTENCY; EVOLUTIONARY HOMOLOGY; FUNCTIONAL HOMOLOGY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; LEUKEMIA CELL; MOLECULAR MODEL; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; SEQUENCE HOMOLOGY; STRUCTURAL HOMOLOGY; UBIQUITINATION; X RAY CRYSTALLOGRAPHY; ANALOGS AND DERIVATIVES; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DEFICIENCY; DRUG EFFECTS; ENZYME SPECIFICITY; METABOLISM; PROTEIN DEGRADATION; PROTEIN MOTIF;

AMINO ACID MOTIFS; ANTINEOPLASTIC AGENTS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DNA-BINDING PROTEINS; HUMANS; IKAROS TRANSCRIPTION FACTOR; MODELS, MOLECULAR; MULTIPROTEIN COMPLEXES; PEPTIDE HYDROLASES; PEPTIDE TERMINATION FACTORS; PHENYLUREA COMPOUNDS; PROTEIN BINDING; PROTEOLYSIS; SUBSTRATE SPECIFICITY; THALIDOMIDE; UBIQUITIN-PROTEIN LIGASES;

EID: 84978715161     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature18611     Document Type: Article

References (34)

1. Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345-1350 (2010).
2. Dimopoulos, M. A., Richardson, P. G., Moreau, P., Anderson, K. C. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat. Rev. Clin. Oncol. 12, 42-54 (2015).
3. Lopez-Girona, A. et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26, 2326-2335 (2012).
4. Zhu, Y. X. et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118, 4771-4779 (2011).
5. Krönke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1? in del(5q) MDS. Nature 523, 183-188 (2015).
6. Angers, S. et al. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 443, 590-593 (2006).
7. Higa, L. A. et al. CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation. Nat. Cell Biol. 8, 1277-1283 (2006).
8. Jin, J., Arias, E. E., Chen, J., Harper, J. W., Walter, J. C. A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol. Cell 23, 709-721 (2006).
9. He, Y. J., McCall, C. M., Hu, J., Zeng, Y., Xiong, Y. DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases. Genes Dev. 20, 2949-2954 (2006).
10. Chamberlain, P. P. et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat. Struct. Mol. Biol. 21, 803-809 (2014).
11. Fischer, E. S. et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512, 49-53 (2014). 10.1038/nature13527.
12. John, L. B., Ward, A. C. The Ikaros gene family: transcriptional regulators of hematopoiesis and immunity. Mol. Immunol. 48, 1272-1278 (2011).
13. Dijon, M. et al. The role of Ikaros in human erythroid differentiation. Blood 111, 1138-1146 (2008).
14. Gandhi, A. K. et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br. J. Haematol. 164, 811-821 (2014).
15. Krönke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301-305 (2014).
16. Lu, G. et al. The myeloma drug lenalidomide promotes the cereblondependent destruction of Ikaros proteins. Science 343, 305-309 (2014).
17. Cheng, Z. et al. Structural insights into eRF3 and stop codon recognition by eRF1. Genes Dev. 23, 1106-1118 (2009).
18. Preis, A. et al. Cryoelectron microscopic structures of eukaryotic translation termination complexes containing eRF1-eRF3 or eRF1-ABCE1. Cell Reports 8, 59-65 (2014).
19. Zhouravleva, G. et al. Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factors, eRF1 and eRF3. EMBO J. 14, 4065-4072 (1995).
20. Hon, W. C. et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 417, 975-978 (2002).
21. Min, J. H. et al. Structure of an HIF-1?-pVHL complex: hydroxyproline recognition in signaling. Science 296, 1886-1889 (2002).
22. Glotzer, M., Murray, A. W., Kirschner, M. W. Cyclin is degraded by the ubiquitin pathway. Nature 349, 132-138 (1991).
23. Sheard, L. B. et al. Jasmonate perception by inositol-phosphate-potentiated COI1-JAZ co-receptor. Nature 468, 400-405 (2010).
24. Tan, X. et al. Mechanism of auxin perception by the TIR1 ubiquitin ligase. Nature 446, 640-645 (2007).
25. Kikuchi, Y., Shimatake, H., Kikuchi, A. A yeast gene required for the G1-to-S transition encodes a protein containing an A-kinase target site and GTPase domain. EMBO J. 7, 1175-1182 (1988).
26. Chauvin, C., Salhi, S., Jean-Jean, O. Human eukaryotic release factor 3a depletion causes cell cycle arrest at G1 phase through inhibition of the mTOR pathway. Mol. Cell. Biol. 27, 5619-5629 (2007).
27. Deshaies, R. J. Protein degradation: prime time for PROTACs. Nat. Chem. Biol. 11, 634-635 (2015).
28. Winter, G. E. et al. Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376-1381 (2015).
29. Lu, J. et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22, 755-763 (2015).
30. Petzold, G., Fischer, E. S., Thomä, N. H. Structural basis of lenalidomideinduced CK1? degradation by the CRL4(CRBN) ubiquitin ligase. Nature 532, 127-130 (2016).
31. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
32. Emsley, P., Lohkamp, B., Scott, W. G., Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486-501 (2010).
33. Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D 67, 355-367 (2011).
34. Bennett, T. A. et al. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine. Clin. Lymphoma Myeloma Leuk. 14, 305-318 (2014).